6 results about "A antigen" patented technology

This invention discloses a method for preparing A, B, and Lewis blood group antigens, wherein the A, B, and Lewis blood group antigens are specifically blood group A. tri Antigen, B tri Antigen, Le a Antigen and Le b Antigen. A one-pot photosensitive method was used to achieve blood group A. tri Antigen, B tri Antigen, Le a Antigen and Le b The method for obtaining large quantities of antigens, as described in this invention, features mild reaction conditions, shortened purification steps, simplicity, high efficiency, environmental friendliness, low cost, and high yield and purity of the target substance. This invention provides a practical and rapid chemical synthesis route for blood type A antigens. tri Antigen, B tri Antigen, Le a Antigen and Le b Antigens provide tools for the development of norovirus vaccines and related antibodies, and therefore have great application prospects.

The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprise a single domain binder, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.

The invention discloses gene modification carrying an immunological enhancement element and application of the gene modification, and relates to the technical field of biological medicine and gene engineering. B, at least one coding nucleic acid sequence IE of an immunological enhancement element, wherein the immunological enhancement element is used for enhancing antigen presentation, immunological co-stimulation signal transmission or positive regulation of a local immune microenvironment; c, at least one of a signal peptide segment SP and a membrane anchoring localization domain TM; the d expression regulation unit comprises a promoter Pr for driving the expression of Ag and IE and a transcription termination signal pA; the e-site strategy related sequence organization comprises a homologous segment left side HS-L and a homologous segment right side HS-R; wherein the Ag and the IE are assembled in the same expression framework, the IE is located at one of the upstream and the downstream of the Ag, antigen presentation and costimulatory signals are synchronous and stable, the immune response intensity and durability are improved, and inter-individual and inter-batch fluctuation is reduced.

The present disclosure is directed to a method of detecting a helminth a antigen in a sample comprising (a) contacting a sample with human antibodies and fragments thereof, comprising clone-paired heavy and light chain CDR sequences, and (b) detecting a helminth antigen in said sample by binding of said human antibody or antibody fragment to a helminth antigen in said sample.

This disclosure relates to immunogenic compositions comprising Borrelia cell surface protein A (OspA) antigen or RNA polynucleotide encoding the OspA antigen, and an adjuvant. In some embodiments, the immunogenic compositions are suitable for stimulating an immune response to Borrelia in a subject. This disclosure also relates to kits of immunogenic compositions, their use, and methods of using them.

The present invention relates to cancer vaccines and methods of treatment using the same. Disclosed is a vaccine composition, the present invention relates to a composition comprising one or more nucleic acids encoding one or more amino acid sequences selected from the group consisting of a tyrosinase, a tyrosinase-associated protein 1, a tyrosinase-associated protein 2, a melanoma-associated antigen 4 protein, a growth hormone releasing hormone, a MART-1 / melan-A antigen, a cancerous testis antigen NY-ESO-1, a cancerous testis antigen NY-ESO-2, the amino acid sequences of the antigen, the Vilms tumor 1 and the human telomerase reverse transcriptase are preferentially expressed in the melanoma. The vaccine compositions may further comprise nucleic acids encoding one or more other antigens, including prostate-specific antigens. Also disclosed are methods of preventing or treating cancer in a subject in need thereof, comprising administering to the subject a vaccine composition comprising a specific amount of cancer antigens to treat or prevent a specific cancer.